Information  X 
Enter a valid email address

Mobeus Inc&Gwth 4 (MIG4)

  Print          Annual reports

Thursday 02 April, 2020

Mobeus Inc&Gwth 4

Issue of Equity

RNS Number : 6453I
Mobeus Income & Growth 4 VCT PLC
02 April 2020
 

 

 

Mobeus Income & Growth 4 VCT plc (the "Company")

 

2 April 2020

 

Issue of Equity

 

The Company announces that on 2 Apr 2020 it allotted and issued 3,482,579   new Ordinary Shares of 1p each ("Shares").  These new Shares in the Company have been issued pursuant to the Offer for subscription with The Income & Growth VCT plc, Mobeus Income & Growth VCT plc and Mobeus Income & Growth VCT plc , launched on 25 October 2019 , to raise up to £60.1 million in aggregate, which includes the utilisation of a £20 million over-allotment facility ("the Offer ").

 

In accordance with the allotment formula set out in the prospectus for the Offer, the Shares were issued at prices of between 69.00 and 65.81 pence per Share, depending on the adviser charge (if applicable) and the number of shares issued (after taking roundings into account) pertaining to each application. 

 

Application has been made for the new Ordinary Shares to be admitted to the Official List of the UK Listing Authority and dealings are expected to commence on or around 3 April 2020.

 

Following this allotment, the issued share capital and total voting rights of the Company are 85,249,664 Ordinary Shares of 1p each.

 

The Company's offer for subscription, as set out in the Prospectus published on 25 October 2019, has reached the maximum number of subscriptions and all the shares have been allotted. The offer is now closed.

 

For further information please contact:

 

Mobeus Equity Partners LLP,

Company Secretary, on 020 7024 7600.

 

 

 

 

 

 

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
IOEKKBBNPBKDFQK

a d v e r t i s e m e n t